Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Bodei

Showing results (81-90 of 184) with videos related to

Pageof 19
Sort By:
Medicine|February 3, 2018
Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case reportGiuseppe Corrias, Natally Horvat, Serena Monti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2007
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)Jan Tennvall, Manfred Fischer, Angelika Bischof Delaloye, et al.
Gynecologic Oncology|June 16, 2004
Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?Chiara Grana, Mirco Bartolomei, Daria Handkiewicz, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 1, 2008
Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposalMaria Vittoria Davì, Lisa Bodei, Marco Ferdeghini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2013
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumoursStefano Severi, Oriana Nanni, Lisa Bodei, et al.
Endocrine-Related Cancer|June 30, 2016
Myeloid neoplasms after chemotherapy and PRRT: myth and realityLisa Bodei, Irvin M Modlin, Markus Luster, et al.
The Oncologist|August 31, 2018
Assessment of NETest Clinical Utility in a U.S. Registry-Based StudyEric Liu, Scott Paulson, Anthony Gulati, et al.
Nature Reviews. Clinical Oncology|February 28, 2019
Time for a change and to adopt a novel molecular genomic approach in NETsLisa Bodei, Eric Liu, Scott Paulson, et al.
Neuroendocrinology|February 9, 2013
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumorsMaddalena Sansovini, Stefano Severi, Alice Ambrosetti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2018
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclidesDaria Handkiewicz-Junak, Thorsten D Poeppel, Lisa Bodei, et al.
Pageof 19

Showing results (81-90 of 184) with videos related to

Sort By:
Pageof 19
Medicine|February 3, 2018
Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case reportGiuseppe Corrias, Natally Horvat, Serena Monti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2007
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)Jan Tennvall, Manfred Fischer, Angelika Bischof Delaloye, et al.
Gynecologic Oncology|June 16, 2004
Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?Chiara Grana, Mirco Bartolomei, Daria Handkiewicz, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 1, 2008
Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposalMaria Vittoria Davì, Lisa Bodei, Marco Ferdeghini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2013
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumoursStefano Severi, Oriana Nanni, Lisa Bodei, et al.
Endocrine-Related Cancer|June 30, 2016
Myeloid neoplasms after chemotherapy and PRRT: myth and realityLisa Bodei, Irvin M Modlin, Markus Luster, et al.
The Oncologist|August 31, 2018
Assessment of NETest Clinical Utility in a U.S. Registry-Based StudyEric Liu, Scott Paulson, Anthony Gulati, et al.
Nature Reviews. Clinical Oncology|February 28, 2019
Time for a change and to adopt a novel molecular genomic approach in NETsLisa Bodei, Eric Liu, Scott Paulson, et al.
Neuroendocrinology|February 9, 2013
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumorsMaddalena Sansovini, Stefano Severi, Alice Ambrosetti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2018
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclidesDaria Handkiewicz-Junak, Thorsten D Poeppel, Lisa Bodei, et al.
Pageof 19